Thursday, February 20, 2014

Biosensors International -Below expectations on continued Japan weakness, pricing pressure(GS)

Biosensors International Group Ltd.
Price (S$) 0.87
12 month price target (S$) 0.93
Below expectations on continued Japan weakness, pricing pressure

What surprised us
Biosensors (BIG) reported 3Q/9MFY14 results that were below our expectations, with revenues of US$82/242 mn, +1%/-2% yoy (FY14 GHe +3%) and NPAT of US$11.1/34.5 mn, down 54%/60% yoy (FY14 GHe -44%). Interventional Cardiology (IVP) sales increased 2% yoy (vs. -7%/+7% in 1Q/2Q) as volume growth (double digit in EMEA/APAC) offset price reductions.


Royalties revenue dropped 21% yoy (vs. -33%/-25% in 1Q/2Q) as sales in Japan remained weak, yet 3Q royalties stabilized qoq as Nobori sales picked up as growth in the sale of new products from competitors (e.g. Abbott’s XIENCE Xpedition launched in July 2013) levelled off post the introduction phase. GP margin dropped 741bps yoy (vs. -573bps/ -681bps in 1Q/2Q) due to the consolidation of Spectrum Dynamics with a GPM of c.48%. Co-promotion of Nobori DES with Terumo in Japan also contributed to the drop in GPM. Management guided to FY14 sales being comparable to FY13, citing lower ASP/royalty revenue.

What to do with the stock
We remain Neutral as we attribute the 3QFY14 miss to the continued slowdown in the Japanese stent market and downward pricing pressure in the stent market worldwide. The lack of compelling new product launches from Biosensor’s IVP and other product segments may continue to weigh on growth. Valuation: We reduce our revenue/EPS forecasts by 2%-9%/ 16%-18% for FY14E-16E to reflect lower IVP sales. Thus, we cut our 12-m EV/GCI vs. CROCI/WACC-based TP to S$0.93 (from S$1.01), implying 7% upside potential and 25X/21X FY14E/15E recurring P/E. Risk: Upside/downside: Uncertainty of pricing and regulatory approval.



Source/Extract/Excerpts/来源/转贴/摘录: Goldman Sachs
Publish date: 13/02/14

No comments:

Post a Comment

Warren E. Buffett(沃伦•巴菲特)
Be fearful when others are greedy, and be greedy when others are fearful
别人贪婪时我恐惧, 别人恐惧时我贪婪
投资只需学好两门课: 一,是如何给企业估值,二,是如何看待股市波动
吉姆·罗杰斯(Jim Rogers)
“错过时机”胜于“搞错对象”:不会全军覆没!”
做自己熟悉的事,等到发现大好机会才投钱下去

乔治·索罗斯(George Soros)

“犯错误并没有什么好羞耻的,只有知错不改才是耻辱。”

如果操作过量,即使对市场判断正确,仍会一败涂地。

李驰(中国巴菲特)
高估期间, 卖对, 不卖也对, 买是错的。
低估期间, 买对, 不买也是对, 卖是错的。

Tan Teng Boo


There’s no such thing as defensive stocks.Every stock can be defensive depending on what price you pay for it and what value you get,
冷眼(冯时能)投资概念
“买股票就是买公司的股份,买股份就是与陌生人合股做生意”。
合股做生意,则公司股份的业绩高于一切,而股票的价值决定于盈利。
价值是本,价格是末,故公司比股市重要百倍。
曹仁超-香港股神/港股明灯
1.有智慧,不如趁势
2.止损不止盈
成功者所以成功,是因为不怕失败!失败者所以失败,是失败后不再尝试!
曾淵滄-散户明灯
每逢灾难就是机会,而是在灾难发生时贱价买股票,然后放在一边,耐性地等灾难结束
  • Selected Indexes 52 week range

  • Margin of Safety

    Investment Clock

    World's First Interactive Investment Clock